Xiao-Fei Sun1,
Salam Pradeep Singh2 
For correspondence:- Salam Singh Email: salampradeep@gmail.com Tel:+918486268935
Accepted: 27 February 2023 Published: 31 March 2023
Citation: Sun X, Singh SP. Network pharmacology integrated molecular docking demonstrates the therapeutic mode of Panax ginseng against ovarian cancer. Trop J Pharm Res 2023; 22(3):589-596 doi: 10.4314/tjpr.v22i3.16
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the mode of action of the active ingredients of Panax ginseng against ovarian cancer protein targets elucidated using a network pharmacology approach and molecular docking study.
Methods: An integrated protein-protein interactions (PPI) network targeting ovarian cancer and P. ginseng was constructed using a network pharmacology approach and molecular docking was carried out for the active constituents of P. ginseng against the target protein of P. ginseng.
Results: Ninety-six compounds were used for the molecular docking simulation against five different proteins from a PPI network of proteins linked to ovarian cancer. The protein-ligand interaction showed strong molecular interaction at the active site of the proteins (p < 0.05).
Conclusion: Ginsenosides and their derivatives present in P. ginseng successfully inhibit several key enzymes and proteins associated with ovarian cancer, which may act as potential therapeutic targets for the disease.
Archives
News Updates
Fulltext in PDF